Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Further Reading from MarketBeat Is Abbott's January Pullback a Good Time to Buy? Submitted by Thomas Hughes. Originally Published: 1/24/2026. 
At a Glance - Abbott Laboratories’ January pullback looks driven more by sentiment than fundamentals, putting shares back near a prior accumulation zone.
- Quarterly results showed solid sales growth, improving margins, and faster adjusted earnings growth despite a revenue miss.
- A long dividend-growth track record and potential upside implied by analyst targets underpin the bullish rebound case.
Abbott Laboratories (NYSE: ABT)'s January 2026 price pullback makes the stock look attractively valued. The move appears driven more by market angst than by company-specific weakness and looks like a knee-jerk overreaction that has returned the shares to a buy zone. 
Some analysts are revisiting historical monetary resets and the role gold has played when governments faced large debt imbalances.
A new free report examines how gold was previously revalued to support national balance sheets, why recent comments from policymakers and investors have renewed interest in this topic, and what individuals may want to understand about protecting long-term savings during periods of monetary change. Download the free report here The zone in question aligns with market action from 2022 to 2024, when Abbott was recovering from its post-COVID-19 revenue contraction and institutions were actively accumulating the stock. Abbott Laboratories Growth Accelerates The most that can be said about Abbott Laboratories' Q4 results and guidance is that some metrics missed market expectations. Still, revenue of $11.46 billion was up 4.5% year-over-year, margins improved, and adjusted earnings accelerated. Revenue growth lagged consensus by several hundred basis points, but stronger margins helped offset the shortfall: adjusted earnings per share (EPS) rose about 12%, slightly above consensus. By segment, the results highlighted the strength of Abbott’s diversified healthcare portfolio. The Nutrition and Diagnostics segments contracted—Nutrition declined nearly 9%—but that weakness was offset by solid gains in Established Pharmaceuticals and Med Tech. The pharma segment grew roughly 9%, driven by generics and emerging markets, while Med Tech expanded about 12.3% with broad-based strength across sub-segments. Margin news was also positive, even if it fell short of some analyst forecasts. A product-mix shift, strength in Med Tech, reduced COVID-19-related sales and operational improvements pushed margins ahead of forecasts. Management expects improvement to continue, forecasting roughly 10% earnings growth in 2026—outpacing revenue—and sufficient cash flow to sustain its capital-return program. Abbott’s capital returns are central to the investment case. The company is a Dividend King, having raised its payout for more than 50 consecutive years, and appears positioned to continue doing so. After the pullback the stock yields about 2.5%, and the company distributes under 50% of consensus earnings, leaving room for share buybacks and other uses of cash that help offset dilutive compensation. Analysts Point to Robust Rebound in Abbott Laboratories Stock Some analysts noted the revenue miss, but the morning of the release saw no major rating or price-target cuts. The prevailing view is that this remains a fundamentally healthy company that can continue returning capital while investing in growth. The consensus share price target reported by MarketBeat implies as much as ~30% upside from current levels, potentially setting new all-time highs, and even the lower-end targets imply some upside. Abbott’s near-term catalysts include an expanding Med Tech portfolio, AI integration across operations and products, widening margins and targeted acquisitions. The acquisition of Exact Sciences is one example of a deal that could broaden revenue and profit streams and deepen the product pipeline. The stock's decline has been sharp and could deepen, but institutions were buyers through 2025 and are likely inclined to add at discounted prices. Technical support appears near $105–$110, though that level is not yet confirmed. Shares could dip to the low end of the target buy zone—around $95 or lower—before rebounding.
| 
